FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2023495362> ?p ?o ?g. }

• W2023495362 endingPage "1180" @default.
• W2023495362 startingPage "1172" @default.
• W2023495362 abstract "Objective To validate post-transrectal ultrasonography (TRUS) prostate biopsy (bx) urine samples for PCA3 messenger ribonucleic acid testing, including correlation of PCA3 score with concurrent bx findings. Methods From July 2008 to July 2010, 2015 patients had urine collected immediately after a TRUS-guided prostate bx. Excluded were men with history of prostate carcinoma (CaP), <6 or ≥24 bx cores, and/or prostate-specific antigen (PSA) level ≥50 ng/mL, resulting in 1909 included men. PCA3 and PSA messenger ribonucleic acid were quantitated using transcription-mediated amplification. A PCA3 score of ≥35 was considered positive. Results Mean and median ages were 66 years. Mean and median PSA levels were 6.7 and 5.1 ng/mL, respectively. Bxs were benign in 970 (50.8%), CaP in 726 (38%), high-grade prostatic intraepithelial neoplasia (HGPIN) in 124 (6.5%), and atypical in 89 (4.7%). PCA3 test was informative in 1887 (98.8%) patients. Means ± standard deviations (median) of PCA3 scores for benign, HGPIN, atypical, and CaP were 22.3 ± 27.9 (12.8), 37.6 ± 43.2 (24.1), 35.7 ± 36.2 (25.7), and 46.9 ± 48.1 (31.6; P <.05 benign vs CaP, benign vs HGPIN and atypical, HGPIN and atypical vs CaP). Sensitivity and specificity of PCA3 for CaP were 46.3% and 78.7%, respectively. CaP risk increased with progressively higher PCA3 score ranges from 14.8% for PCA3 <5 to 66.7% for PCA3 >100. Area under the curve (AUC) for the PCA3 receiver operating characteristics was not significantly different in men without prior bx (AUC = 0.716) compared with men with at least 1 prior nonpositive bx (AUC = 0.702). Conclusion Post-TRUS bx urine is a valid sample for PCA3 testing. Patients with a negative bx and a positive PCA3 test may have a higher likelihood of unsampled CaP. To validate post-transrectal ultrasonography (TRUS) prostate biopsy (bx) urine samples for PCA3 messenger ribonucleic acid testing, including correlation of PCA3 score with concurrent bx findings. From July 2008 to July 2010, 2015 patients had urine collected immediately after a TRUS-guided prostate bx. Excluded were men with history of prostate carcinoma (CaP), <6 or ≥24 bx cores, and/or prostate-specific antigen (PSA) level ≥50 ng/mL, resulting in 1909 included men. PCA3 and PSA messenger ribonucleic acid were quantitated using transcription-mediated amplification. A PCA3 score of ≥35 was considered positive. Mean and median ages were 66 years. Mean and median PSA levels were 6.7 and 5.1 ng/mL, respectively. Bxs were benign in 970 (50.8%), CaP in 726 (38%), high-grade prostatic intraepithelial neoplasia (HGPIN) in 124 (6.5%), and atypical in 89 (4.7%). PCA3 test was informative in 1887 (98.8%) patients. Means ± standard deviations (median) of PCA3 scores for benign, HGPIN, atypical, and CaP were 22.3 ± 27.9 (12.8), 37.6 ± 43.2 (24.1), 35.7 ± 36.2 (25.7), and 46.9 ± 48.1 (31.6; P <.05 benign vs CaP, benign vs HGPIN and atypical, HGPIN and atypical vs CaP). Sensitivity and specificity of PCA3 for CaP were 46.3% and 78.7%, respectively. CaP risk increased with progressively higher PCA3 score ranges from 14.8% for PCA3 <5 to 66.7% for PCA3 >100. Area under the curve (AUC) for the PCA3 receiver operating characteristics was not significantly different in men without prior bx (AUC = 0.716) compared with men with at least 1 prior nonpositive bx (AUC = 0.702). Post-TRUS bx urine is a valid sample for PCA3 testing. Patients with a negative bx and a positive PCA3 test may have a higher likelihood of unsampled CaP." @default.
• W2023495362 created "2016-06-24" @default.
• W2023495362 creator A5000355612 @default.
• W2023495362 creator A5011185573 @default.
• W2023495362 creator A5014739663 @default.
• W2023495362 creator A5040639312 @default.
• W2023495362 creator A5044822713 @default.
• W2023495362 creator A5048035907 @default.
• W2023495362 creator A5052991186 @default.
• W2023495362 creator A5083756700 @default.
• W2023495362 date "2014-11-01" @default.
• W2023495362 modified "2023-09-25" @default.
• W2023495362 title "Reflex PCA3 Messenger Ribonucleic Acid Testing: Validation of Postbiopsy Urine Samples and Correlation With Prostate Biopsy Findings in ∼2000 Patients" @default.
• W2023495362 cites W1518170435 @default.
• W2023495362 cites W1579882000 @default.
• W2023495362 cites W1979759722 @default.
• W2023495362 cites W1987998253 @default.
• W2023495362 cites W2009746555 @default.
• W2023495362 cites W2019776469 @default.
• W2023495362 cites W2024097324 @default.
• W2023495362 cites W2024198638 @default.
• W2023495362 cites W2042458623 @default.
• W2023495362 cites W2054217474 @default.
• W2023495362 cites W2060053683 @default.
• W2023495362 cites W2087960334 @default.
• W2023495362 cites W2089798048 @default.
• W2023495362 cites W2091288012 @default.
• W2023495362 cites W2091654201 @default.
• W2023495362 cites W2097265742 @default.
• W2023495362 cites W2097876373 @default.
• W2023495362 cites W2098905361 @default.
• W2023495362 cites W2103263363 @default.
• W2023495362 cites W2112226957 @default.
• W2023495362 cites W2116874887 @default.
• W2023495362 cites W2119529879 @default.
• W2023495362 cites W2121518947 @default.
• W2023495362 cites W2130805253 @default.
• W2023495362 cites W2146294552 @default.
• W2023495362 cites W2157784108 @default.
• W2023495362 cites W2158341993 @default.
• W2023495362 cites W2169983315 @default.
• W2023495362 cites W2328176404 @default.
• W2023495362 doi "https://doi.org/10.1016/j.urology.2014.05.067" @default.
• W2023495362 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/25443926" @default.
• W2023495362 hasPublicationYear "2014" @default.
• W2023495362 type Work @default.
• W2023495362 sameAs 2023495362 @default.
• W2023495362 citedByCount "0" @default.
• W2023495362 crossrefType "journal-article" @default.
• W2023495362 hasAuthorship W2023495362A5000355612 @default.
• W2023495362 hasAuthorship W2023495362A5011185573 @default.
• W2023495362 hasAuthorship W2023495362A5014739663 @default.
• W2023495362 hasAuthorship W2023495362A5040639312 @default.
• W2023495362 hasAuthorship W2023495362A5044822713 @default.
• W2023495362 hasAuthorship W2023495362A5048035907 @default.
• W2023495362 hasAuthorship W2023495362A5052991186 @default.
• W2023495362 hasAuthorship W2023495362A5083756700 @default.
• W2023495362 hasConcept C121608353 @default.
• W2023495362 hasConcept C126322002 @default.
• W2023495362 hasConcept C126894567 @default.
• W2023495362 hasConcept C2775934546 @default.
• W2023495362 hasConcept C2776235491 @default.
• W2023495362 hasConcept C2780026642 @default.
• W2023495362 hasConcept C2780192828 @default.
• W2023495362 hasConcept C2781217009 @default.
• W2023495362 hasConcept C2781406297 @default.
• W2023495362 hasConcept C29456083 @default.
• W2023495362 hasConcept C58471807 @default.
• W2023495362 hasConcept C71924100 @default.
• W2023495362 hasConcept C87874733 @default.
• W2023495362 hasConceptScore W2023495362C121608353 @default.
• W2023495362 hasConceptScore W2023495362C126322002 @default.
• W2023495362 hasConceptScore W2023495362C126894567 @default.
• W2023495362 hasConceptScore W2023495362C2775934546 @default.
• W2023495362 hasConceptScore W2023495362C2776235491 @default.
• W2023495362 hasConceptScore W2023495362C2780026642 @default.
• W2023495362 hasConceptScore W2023495362C2780192828 @default.
• W2023495362 hasConceptScore W2023495362C2781217009 @default.
• W2023495362 hasConceptScore W2023495362C2781406297 @default.
• W2023495362 hasConceptScore W2023495362C29456083 @default.
• W2023495362 hasConceptScore W2023495362C58471807 @default.
• W2023495362 hasConceptScore W2023495362C71924100 @default.
• W2023495362 hasConceptScore W2023495362C87874733 @default.
• W2023495362 hasIssue "5" @default.
• W2023495362 hasLocation W20234953621 @default.
• W2023495362 hasLocation W20234953622 @default.
• W2023495362 hasOpenAccess W2023495362 @default.
• W2023495362 hasPrimaryLocation W20234953621 @default.
• W2023495362 hasRelatedWork W1979374145 @default.
• W2023495362 hasRelatedWork W2041562209 @default.
• W2023495362 hasRelatedWork W2047986592 @default.
• W2023495362 hasRelatedWork W2099948048 @default.
• W2023495362 hasRelatedWork W2102167265 @default.
• W2023495362 hasRelatedWork W2105000714 @default.
• W2023495362 hasRelatedWork W2148869351 @default.
• W2023495362 hasRelatedWork W2390982334 @default.
• W2023495362 hasRelatedWork W2566665866 @default.
• W2023495362 hasRelatedWork W3082324229 @default.

• next